Etomoxir

Research use only, not for human use.

An irreversible inhibitor of carnitine palmitoyltransferase-1 (CPT-1) that inhibits fatty acid β-oxidation in rat liver with IC50 of 5-20 nM.

An irreversible inhibitor of carnitine palmitoyltransferase-1 (CPT-1) that inhibits fatty acid β-oxidation in rat liver with IC50 of 5-20 nM; affects ketogenesis, cholesterol synthesis, and gluconeogenesis both in vitro and in vivo; decreases viability in LNCaP, VCaP, and patient-derived benign and prostate cancer cells, associated with decreased AR expression, decreased mTOR signaling, and increased caspase-3 activation; decreases xenograft growth in mice.Heart Failure Phase 2 Discontinued

Etomoxir; B 807-54;B80754; B-80754; (R)-(+)-Etomoxir

Others

Other Targets

Other Targets

Metabolic Disease

——

124083-20-1

326.82

C17H23ClO4

>98% (HPLC)

10 mM in DMSO

O=C([C@]1(CCCCCCOC2=CC=C(Cl)C=C2)OC1)OCC

2-Oxiranecarboxylic acid, 2-[6-(4-chlorophenoxy)hexyl]-, ethyl ester, (2R)-

(-20℃)

With Ice Pack

≥ 2 years